HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dexter Yan

Senior Reporter

Shanghai, China

Dexter Yan is a senior writer covering China’s surging pharma industry on the APAC Pharma news team. With a keen interest in R&D and commercial activities taking place around the clock, he is always on the lookout for opportunities to keep readers better informed of any developments in the field.

Latest From Dexter Yan

Chinese Biotechs Raise $212m Through Major VC/PE Deals in November

Leading the group were Trinomab Biotech, which develops antibodies for infectious diseases, and cell and gene developers BRL Medicine and XellSmart.

China Financing

Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics

Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.

Deal Watch Business Strategies

Full-Life Expands Radiopharmaceutical Reach With $245m Focus-X Buyout

Full-Life’s acquisition of Focus-X came after two other Chinese biotechs leaped into the fray for a leading position in China’s nascent radionuclide therapy market.

China M & A

China RNA Activation Venture Ractigen Looks To Clinic For Validation

A China returnee CEO has raised roughly $50m for his bioventure that is looking to clinically validate and commercialize an RNA activation platform he co-discovered while working in the US.

China Research & Development

Chinese Pharma Looks To Out-Licensing As Domestic Downturn Bites

China's biopharma firms including Hengrui Medicine and HUTCHMED actively pursue licensing partners for their drug assets as the economic downturn caused by domestic COVID flare-ups continues worsening. Meanwhile, there are some predictions that smaller biotechs in the country may need to tap into multinationals' deep pockets to raise new funds.

China Deals

Govt-Led Innovation Support In Focus As Shanghai Biopharma Sector Rebounds

Shanghai’s biopharma sector has started to regain momentum and is beginning to see its innovation bets paying off, with support from the local government.

China Strategy
See All
UsernamePublicRestriction

Register